New strategies for the design and development of protein antimicrobials based on phage products
Nowadays, antibiotic resistance is one of the most urgent global health issues to be tackled. Among the infective bacteria, Gram-negative ones are the main causative agents of nosocomial infections, causing an important death burden, partly due to anti-microbial resistance. Currently, phage therapy...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/5646 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/5646 |
| Access Level: | acceso abierto |
| Palabra clave: | 577.18.08(043.2) Antiobitcs Antibióticos Medicamentos |
| Sumario: | Nowadays, antibiotic resistance is one of the most urgent global health issues to be tackled. Among the infective bacteria, Gram-negative ones are the main causative agents of nosocomial infections, causing an important death burden, partly due to anti-microbial resistance. Currently, phage therapy research is experiencing a renaissance as a viable alternative or complement to common antimicrobial chemotherapy. Not only complete virion particles but also phage-derived products have a series of advantages over antibiotics. In particular, phage (endo)lysins are the phage-encoded proteins re-sponsible for bacterial host lysis and subsequent death due to their cell wall lytic activity. Lysins are being repurposed to be exogenously applied, in a purified form, against bac-teria, functioning as lytic antimicrobials, and thus are also called ‘enzybiotics’. Among the many advantages of enzybiotics, we may cite their lower chance to provoke resistance in the target bacteria and their versatility to be screened and engineered using bioinfor-matic and biotechnological tools... |
|---|